Upload File

km c364e-20170627131943 pharma.pdfpkk capturing kirschgartenstr. pcc disclosure by teva pharma ag,...

  • Home
  • Documents
  • KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
12

Upload: others

Post on 17-Mar-2020

4 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 2: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 3: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 4: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 5: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 6: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 7: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 8: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 9: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 10: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 11: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:
Page 12: KM C364e-20170627131943 Pharma.pdfPKK Capturing Kirschgartenstr. PCC Disclosure by Teva Pharma AG, Date of the Donation/ 14, 4010 Basel Event & Place Teva Pharma AG Date of disclosure:

Pioglitazon Teva Pharma, INN-pioglitazone hydrochloride · Pioglitazon Teva Pharma 45 mg tablete Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida). Za celoten

Budesonide/Formoterol Teva Pharma B.V., INN … · revalúen periódicamente a los pacientes para que la dosis de Budesónida/Formoterol Teva Pharma B.V. siga siendo la óptima

Zoledronic acid Teva Pharma, INN-zoledronic acid

Teva 2017 Social Impact Report - Teva Hong Kong · Teva 2017 Social Impact Report Messages from Teva A message from our President & CEO, Kåre Schultz Teva has a rich history of providing

Docetaxel Teva Pharma, INN-docetaxel

Zoledronic acid Teva Pharma, INN-zoledronic acid · 2 1. BEZEICHNUNG DES ARZNEIMITTELS Zoledronsäure Teva Pharma 5 mg Infusionslösung in Flaschen 2. QUALITATIVE UND QUANTITATIVE

Budesonide/Formoterol Teva Pharma B.V., INN-Budesonide and

Clopidogrel Teva Pharma, INN-clopidogrel

CISPLATIN NEPHROTOXICITY AGGRAVATED BY …erj.ersjournals.com/content/erj/early/2010/07/22/09031936.00055110... · Cp was provided by TEVA Hungary and EBEWE Pharma (Unterach, Austria)

9. Janssen Pharma v. Teva Pharms

Docetaxel Teva Pharma, INN-docetaxel · Docetaxel Teva Pharma 40 mg/ml, concentrate for solution for infusion is a clear viscous yellow to yellow-brown solution. It is supplied with

Natco Pharma Limitednatcopharma.co.in/wp-content/uploads/2016/02/Natco-Investor... · Important Disclosure 2 This presentation has been prepared by Natco Pharma Limited (the “Company”)solely

Itzhak Krinsky, Ph.D, Corporate VP – Business Development ...€¦ · Strong International market growth 17 Source: 2009 – 2013 IMS Market Prognosis – Constant fx, Teva Pharma

Non-Classified Drugs - Alberta Blue Cross · apo-cephalex auro-cephalexin teva-cephalexin apo-cephalex auro-cephalexin teva-cephalexin teva-cephalexin teva-cephalexin teva-cephalexin

Ribavirin Teva Pharma B.V., INN-ribavirin...kurių HCV-RNR teigiamas. Sprendžiant neatidėti gydymo iki pilnametystės, svarbu atsižvelgti, kad gydymas deriniu sukėlė augimo slopinimą,

Teva Pharmaceuticals

No. CITY OF NEW HAVEN, SUPERIOR COURT …...vs. PURDUE PHARMA L.P., d/b/a PURDUE PHARMA (DELAWARE) LIMITED PARTNERSHIP; PURDUE PHARMA INC.; THE PURDUE FREDERICK COMPANY, INC.; TEVA

NATCO Pharma Limited Expanding Horizons / Important Disclosure 2 This presentation has been prepared by Natco Pharma Limited (the “Company”) solely for information purposes without

Discontinued Items - Smith Drug Company · 609883 1ct Loratadine Syrup SF 4oz Grape 120mL 51672209208 Taro Pharma 300889 1ct Galantamine ER Cap 16mg 30ct 00555102101 Teva Pharma 090183

Teva broshura

PARTICIPANT LIST · PDF fileEli Lilly Australia ... George Fischer George Weston Foods (Australia) GHD Gilead Sciences Givaudan Australia ... Teva Pharma Australia

Generic Pharma: Excellence Within a Rapidly …...Teva, widely acknowledged as the global generic drug industry’s leader (ranked 10th by IMS as among the top 20 pharma manufacturers

Neue Arzneimittel 2013/2014 - akdae.de · Evidence, Hoffman-La Roche, IMS Health, Novartis Pharma, PMRA Consulting, PriceSpective, TEVA-ratiopharm, Kantar Health . 120. Kongress der

Budesonide/Formoterol Teva Pharma B.V., INN … · Assessment report - Budesonide/Formoterol Teva Pharma B.V. EMA/83618/2020 Page 6/67 1. Background information on the procedure 1.1

Risk Management in the Pharma Magdolna Morvai · PDF fileRisk Management in the Pharma Industry 55th EOQ Congress Budapest, Hungary June 20-23, 2011 Magdolna Morvai TEVA Pharmaceutical

"Una comunidad de aprendizaje" Experiencia Teva Pharma

Future of Pharma - trends in pharma and impact on manufacturing - conference keynote speaker on parma industry for TEVA

Takeda Pharmaceutical Company - SUMMARY OF FINANCIAL … · 2017. 5. 10. · (Note3) Teva Takeda Yakuhin Ltd. is a wholly owned subsidiary of Teva Takeda Pharma Ltd. which is 49%

CLINICAL TRIAL DISCLOSURE AND RESULTS …...DISCLOSURE AND RESULTS REPORTING Marc Wilenzick, Esq. Pharma Regulatory & Compliance Conference Washington, DC (November 2012) Clinicaltrials.gov

Teva UK Holdings Limited, Ivax UK Limited, Teva Pharma

ANNEXE I RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUITec.europa.eu/.../2016/20160706135330/anx_135330_fr.pdf · Budesonide/Formoterol Teva Pharma B.V., il est recommandé de passer à

Teva Pharmaceutical Industries (TEVA) Earnings Report: Q4 ...s.t.st/media/xtranscript/2015/Q1/13037740.pdf · Teva Pharmaceutical Industries (TEVA) Earnings Report: Q4 2014 Conference

Outsourced Faculty of TEVA Pharma

DISCLOSURE SUMMARY - IASLC WCLC 2017wclc2017.iaslc.org/.../10/WCLC2017-Financial_Disclosure_Summary.pdf · DISCLOSURE SUMMARY . ... Roche Pharma AG, Bristol-Myers Squibb ... Eric

Teva Pharmaceuticals Industries Ltd. (TEVA, Neutral, $60TP)